Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
public s/p is driven by news, aspire's purchase price depends on recent public s/p, hence news affects aspire's purchase price.
FWIW I believe this price action/ news cycle has everything to do with Aspire Capital being given the opportunity to purchase shares at a discount.
Good old fashioned Mexican standoff eh? Who shoots first. Who has deeper pockets? Good luck
My 2 cents regarding PK data:
Leo says "We are anticipating the tests to be run in mid-March and the results to follow shortly thereafter.
Nowhere does he mention, "and shareholders will be updated immediately."
3/14- http://seekingalpha.com/article/1273221-an-interview-with-leo-ehrlich-cellceutix-ceo
We know they are presenting at this years ASCO, and updates to abstracts are due by 4/11, this Thursday. With cohort 3 wrapping up, I'm sure they are rushing to collect and analyze the data for an updated abstract.
Leo says, "The ASCO meeting gives Cellceutix an opportunity to provide a comprehensive update on the latest data from the Kevetrin clinical trials to shareholders and leaders in the scientific community as well as time for interaction with others about possible future collaborations and studies. Furthermore, it showcases Cellceutix’s novel drug and accomplishments to many of the organizations that were first introduced to Kevetrin three years ago when it was recognized at the American Association for Cancer Research as a drug on the ‘frontier’ of cancer research.
Dr. Krishna Menon, Chief Scientific Officer at Cellceutix, commented, “We are still at the early stages of the clinical trial. To date, we have not observed any dose limiting toxicities. Initial pharmacokinetic (PK) data from the clinical trial has been received and is consistent with the animal data, which is a very optimistic sign moving forward. Additional information on these PK studies will be forthcoming at ASCO. We are now looking forward to receiving data from the p21 biomarker studies which is expected in March 2013.”
http://cellceutix.com/cellceutix-abstract-for-annual-american-society-of-clinical-oncology-meeting/
I'm looking forward to:
1. Announcement of the completion of 3rd cohort with no DLT and the start of 4th.
2. Abstracts released on ASCO.org 5/15
3. SW Cancer center PR
"Additional updates on the planned studies testing Kevetrin against Acute Myelogenous Leukemia at the University of Bologna as well as other corporate developments relating to research on Kevetrin at a world-renowned cancer center in the Southwest United States are forthcoming shortly.
4. Start of quick Phase 3 for Prurisol in the next 2 month time-frame. "Upcoming clinical trials in Europe planned for the second quarter of 2013."
-2/25 http://cellceutix.com/cellceutix-reports-on-kevetrin-clinical-trials-and-prurisol-manufacturing/
5. ASCO presentation and comprehensive shareholder update regarding PK and DLT data for Kevetrin.
Thanks for the chuckle.
I also got a kick out of steelyeye's
"European Stereotypes."
Forgive me if this is slightly off topic or has already been discussed. I was reviewing Trovagene's recent 8/10K and a couple of things in the notes looked familiar. I was wondering if there was any correlation?
Can their urine test be used to detect mutations in the gene, that Kevetrin could then help correct in certain patients? Sounds like a good diagnostic/treatment partnership opportunity.
Review of 2012 and 2013 Announcements Demonstrate Progress in Development Programs
* Launched HPV-HR assay, a urine-base molecular human papillomavirus (HPV) test
in 2013.
* Extended planned offering of urine-based oncogene mutation tests to include a
test for the detection of a specific p53 mutation and a specific double
mutation in the hepatitis B virus in 2013.
* Expanded clinical collaboration with the University of Texas MD Anderson
Cancer Center to include the detection of transrenal BRAF mutations in the
urine of patients with advanced or metastatic cancers in 2013 from an initial
collaboration for the detection transrenal KRAS mutation in the urine of
patients with pancreatic cancer in 2012.
* Entered into research collaboration with Brazil's Barretos Cancer Hospital to
evaluate Trovagene's urine-based HPV assay as a potential Pap smear replacement
in 2012.
* Entered into an agreement with India's Strand Life Sciences to validate and
commercialize the HPV assay in India and South Asia in 2012.
* Granted licenses for NPM1 marker for acute myelogenous leukemia to Quest
Diagnostics, Duke University and Genoptix, Inc. in 2012. Received a milestone
payment related to the NPM1 patent issuance from Ipsogen, S.A.
* Strengthened patent portfolio. Received notification of issuance of two U.S.
patents in 2012. Trovagene now has 60 issued patents and 47 pending patents.
* Acquired a CLIA-certified, CAP-approved laboratory in 2012.
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001104659-13-026267%2Etxt&FilePath=%5C2013%5C04%5C02%5C&CoName=TROVAGENE%2C+INC%2E&FormType=8-K&RcvdDate=4%2F2%2F2013&pdf=
Exhibit 99.1
10k looks pretty ugly IMO. Didn't read it thoroughly; just breezed through but didn't like a lot of what I saw.
AH 6.01 print
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001104659-13-026211%2Etxt&FilePath=%5C2013%5C04%5C01%5C&CoName=TROVAGENE%2C+INC%2E&FormType=10-K&RcvdDate=4%2F1%2F2013&pdf=
larger trades executed in pieces by specialized software.
MM needs some action, or else he'll create some action huh
Not sure if you are correct about that but...
if you are, not a good sign.
Question:
Why so many failure to delivers here the last few months?
In some cases, more in one day than the total daily volume. I'm not sure how that's possible but the data reflects it.
Agree,
I openly admit my motive for agreeing is selfish.
I have funds cleared and ready to put to work this week, and I'm hoping news doesn't come until the weekend in order to allow me adequate time to accumulate at discounted prices.
That being said, I'm not overly worried as I've been buying from 1.30 in early to December up into the 1.50s on the dips early this year
:)
If it were a business, trading= intent/ability to hold security < 1 yr or 1 op cycle. Avail-4-sale = intent/ability to hold > 1 yr or 1 op cycle.
I guess we might classify a trader as in/out under a yr, and investor in/out > 1 yr, based on ability and intent.
better hedge and get champagne and xanax, could be used either way.
fwiw
115,478 sold short of 381,597 total traded yesterday.
30% of trades. CTIX has been averaging btwn 25-30% short/day so nothing special.
One possible explanation for new posters, another is fishing.
GL :)
Hey Dan, welcome to i-hub!
Wish I could help you with your question, but I was not a biology major.
Lucky for you, this board is full of people who specialize in that field.. I'm sure someone will help you perform your DD.
Welcome to the site, and the CTIX board!
ICE
Yes, welcome Ivan.
This board is full of helpful, intelligent people that will do you the favor of seeking out/providing relevant information and making sense of it.
Good luck.
CTIX in 2013 :)
exciting, thank you Karin :)
At the end of the day, both Menon and Evans say that human trials and the FDA may initially lead to the disease Kevetrin will be focused on for treatment and approval, but having a drug that can be applied in different areas will be great in the long run.
Evans points out that is not unusual for cancer drugs to get initial approval to treat one area, such as lung cancer (or retinoblastoma;) and then get broader and broader approvals to treat other areas that the drug shows signs of combating. "We would ultimately try to get approval for a range of these indications," he said. "We have potential in a number of different areas and we will try to exploit these areas."
A shift of focus for a drug, initially targeted to treat one type of problem, but found to also treat another, is not unusual for the pharmaceutical industry. Well known examples include Viagra and Rogaine, both of which were initially targeted to treat diseases unrelated to the effects the drugs have now become famous for.
http://www.indusbusinessjournal.com/ME2/dirmod.asp?sid=&nm=&type=Publishing&mod=Publications%3A%3AArticle&mid=8F3A7027421841978F18BE895F87F791&tier=4&id=A2B1C1CB9BEC463FB31CFACA82E6AA45
FORM 8-K
On March 5, 2013 the Company issued 370,500 Class A common shares par value $.0001 to each of two warrant holders upon exercise of Common Stock Purchase Warrants exercisable at $0.25 per share. The Company received an aggregate of $185,250. The issuance was exempt from registration under Section 4(2) of the Securities Act.
370,500 x 2 = 741,000 common added.
http://ih.advfn.com/p.php?pid=nmona&article=56639275&xref=newsalerttweet
Hey Doc, question..
Can you shed some light on this transcript from the recent filing?:
Large amounts of our Class A Common Stock will be eligible for resale under Rule 144.
As of January 15, 2013, approximately 48,446,771of the 95,623,034 outstanding shares of the Company's Class A Common Stock are restricted securities as defined under Rule 144 of the Securities Act and under certain circumstances may be resold without registration pursuant to Rule 144.
Approximately 5,151,201 shares of our restricted shares of Class A Common Stock are held by non-affiliates who may avail themselves of the public information requirements and sell their shares in accordance with Rule 144. As a result, some or all of these shares may be sold in accordance with Rule 144 potentially causing the price of the Company's shares to decline.
In general, under Rule 144, a person (or persons whose shares are aggregated) who has satisfied a six month holding period may, under certain circumstances, sell within any three-month period a number of securities which does not exceed the greater of 1% of the then outstanding shares of Class A Common Stock or the average weekly trading volume of the class during the four calendar weeks prior to such sale. Rule 144 also permits, under certain circumstances, the sale of securities, without any limitation, by a person who is not an Affiliate, as such term is defined in Rule 144(a)(1), of the Company and who has satisfied a one-year holding period. Any substantial sale of the Company's Class A Common Stock pursuant to Rule 144 may have an adverse effect on the market price of the Company's shares. This filing will satisfy certain public information requirements necessary for such shares to be sold under Rule 144.
His/her posts are written this way purposefully in order to maintain as much anonymity as possible, and to avoid a direct link to source IMO.
Either a trader dabbling in borderline stock manipulation techniques, or someone working for an MM trying to create a more volatile market (= more $) IMO.
My guess is trader playing the swings, who also knows the larger trend, so most likely establishing a free ride.
Hope everyone is enjoying their weekend :)
Go CTIX
The author's writing/presentation skills could use some work IMO. It appears to have been written in a hurry. Of course, I try not to judge due to my own imperfections which is why I say "could use some work," as opposed to "has poor writing skills."
In other news... picked up some more 1.50s on Friday.
Go CTIX
A quote to remember:
CEOCFO: Final thoughts, what should people remember most about Cellceutix?
Mr. Ehrlich: The important thing is that they have to know that we have proven management. Our CEO worked at Pfizer for over twenty-five years. He rose to the rank of general counsel of Pfizer's Pharma Division, which accounted for approximately 96% of the total revenue of the company. Our chief scientific officer, who developed our cancer drug, was a group leader of cancer research at Eli Lilly (NYSE: LLY). He was the key developer of two blockbuster cancer drugs named Alimta and Gemzar, which generate billions of dollars in sales. So if this was a horse race, these are the jockeys our shareholders would be going with. I find it very interesting that our founders George Evans along with Krishna Menon decided they would go to a small start-up company to start their own. Obviously, they feel that they could do something different and better.
via CEO/CFO Interviews
http://www.ceocfointerviews.com/interviews/CTIX-Cellceutix10.htm
Hopefully the delay in the 2nd Cohort has provided ample time to prepare Cohort 3, and for a thorough analysis of data from the first 2.
Slow and steady winds the race.
He's a CPA, what would you expect?
What's the #1 Principal of Accounting: Conservatism.
Your statements would have merit, if only they reflected reality.
That accumulation/distribution line calls your bluff. Even though the price may be on hiatus, shares are being accumulated, not dispersed.
To me, it appears that myself and like-minded individuals have been accumulating and holding. These small % dips provide great points to add to a position, and continue holding, which the chart reflects.
Good luck edge, I hope you do not trade based on the opinions you present in your messages.
Ready for the next rally :)
Patience and a plan is usually what pays.
Good luck to everyone on the board.
Thank you for the 1.65s today.
If no PR this long weekend, I'll be adding again Tuesday.
Buy fear/sell greed, but play the larger trend :)
News to expect,
* SW Cancer research center interested in testing Kevetrin against myeloma. As the CEO puts it, “one of the world’s most prominent cancer centers, located in the southwest United States."
http://www.bizjournals.com/boston/blog/bioflash/2012/12/cellceutix-anti-cancer-compound-may-be.html
* Updates on Phase I trial of Kevetrin being conducted at Dana-Farber Cancer Center and partner Beth Israel Deaconess Medical Center.
* Start of Prurisol phase 2/3 30 day proof-of-concept trial in April/May.
* Start of European trials that are being sponsored by and hosted at a leading European University testing Kevetrin against Acute Myelogenous Leukemia (AML), saving the company millions of dollars.
http://cellceutix.com/cellceutix-plans-for-european-funded-leukemia-phase-1-trial/
* ASCO (May 31 to June 4) abstract acceptance for presentation on Kevetrin Phase 1 study. This is good because "it showcases Cellceutix’s novel drug and accomplishments to many of the organizations that were first introduced to Kevetrin three years ago when it was recognized at the American Association for Cancer Research as a drug on the ‘frontier’ of cancer research." Expect a decision to be announced late next month (late March.)
http://cellceutix.com/cellceutix-abstract-for-annual-american-society-of-clinical-oncology-meeting/
* In June after ASCO, I expect the announcement of the Prurisol patent being published with details about the compound. It seems to be exciting information by the way the CEO and others have talked about it, and they've kept it "close to the vest."
http://cellceutix.com/wp-content/uploads/2012/10/Not-an-ordinary-start-up-Cellceutix4.pdf
“It seems that the potential of Kevetrin is starting to circle the globe. This University has a distinguished reputation in hematological diseases,” commented Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. “Our patent has been published. Only when a compound looks extremely promising do major pharmaceutical companies and universities approach a smaller company like Cellceutix. This gives us a great sense of confirmation as to the potential of Kevetrin and validation in our beliefs about the possible robust number of indications where it could provide a therapeutic benefit.”
2013 looks good.
I believe..
we see a dip/weakness the next few weeks.
We've had strength the last few weeks which kept us afloat. This news boosts us up a few points with a slow trickle back to 2 and we zig-zag btwn 1.90-2.10 until something substantial is released. I'd love to be proved wrong and see steady accumulation so let it be,but; my 2 cents. NYR2 keyed me into this ticker mid-DEC and I've payed holiday bills with the profits, much thanks :) Looks good long-term though, love this ticker. I'm a small fish but I support strength and help push momo so fingers x'd for positive results.
Thank you management.
Watching like a hawk here..
Cellceutix Makes Breakthrough in Cancer Research by Activating p53, the "Guardian Angel of the Human Genome."
Dr. Emil Frei: "What Cellceutix is doing with Kevetrin can lead to a groundbreaking moment in the world of oncology..."
Clinical Trials at Dana-Farber and Beth Israel Deaconess / Harvard Cancer Centers.
-transcribed from the Cellceutix website.
http://cellceutix.com/
Great to hear!
Hopefully it's all good news!
Care to share an example of what news management/ fellow investors think may be forthcoming in the 1-2 wk. time-frame?
If this retraced back to 1.20-1.50 I would not be shaken one bit, because I would be loading my boat, and it would add strength to the chart in the long-run (imo.)
I get nervous when I see something too one-sided, balance is much more healthy and sustainable when dealing with the long-term.
Looking forward to a great year here at CTIX!
Same
I wouldn't mind seeing it test the 50DMA.
I would double my position in the 1.20-1.50 range.
My opinion is that's it's possible if there is a 1-2 wk. period without any news.
It all depends on what management has to offer, and what their plan is.
The only thing that really matters is KEVETRIN's efficiency in human clinical trials IMO.
GLTA